Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthca

Introduction

The prescription pharmaceutical market in Australia was valued at $9.1 billion in 2009. Key growth drivers include the growing use of chronic high-value innovative treatments driven by a rising elderly population and high public spending as a proportion of total healthcare expenditure.

Scope

*Overview of Australia's socioeconomics and demographics, healthcare system, regulation, pricing and reimbursement and intellectual property position.

*Assesses the size of Australia's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies.

*Examines Australia's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion.

*Quantifies Australia's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.

Highlights

Australia's health expenditure totaled $81.8 billion, representing 9.1% of gross domestic product (GDP) in the financial year of 200708, which is the same percentage of GDP as the previous year. Australia's health expenditure as a proportion of GDP has been comparable to that seen in Europe, with most of its spending coming from the government.

Lipitor (atorvastatin, Pfizer) generated significantly higher sales than any other brand on the Australian pharmaceutical market in 2009 ($550m). The second and third highest-selling brands, Crestor (rosuvastatin; AstraZeneca) and Nexium (esomeprazole; AstraZeneca), lag far behind Lipitor and did not even reach half of its sales.

Compared with Europe, where 17 biosimilars of five different molecules have been approved since 2006, Australia's biosimilar market is small, particularly in terms of sales at $45,000. Somatropin is the only biologic that has biosimilar versions available, although the market is still very much dominated by the original branded product.

Reasons to Purchase

*Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.

*Quantify the size and growth of the prescription pharmaceutical market in Australia, analyzing key therapy areas, brands and companies.

*Assess drivers and resistors of generic and biosimilars uptake in Australia and the level of erosion brands can expect to face post patent expiry.


Table of Contents :
ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
Geographic-specific reports: 2
Global issue reports: 2
About the Healthcare Asia-Pacific Team 3
1. Australia - Executive Summary 4
Strategic scoping and focus 4
Key findings - healthcare drivers and resistors in Australia 5
Australia - Socio-demographic and economic analysis 8
Socio-demographic trends 8
Socio-economic trends 9
Australia - Healthcare system and drug regulatory analysis 10
Healthcare expenditure 10
Healthcare system overview 11
Regulatory issues 11
Pricing and reimbursement issues 11
Australia - Prescription pharmaceutical sales analysis 14
Pharmaceutical market size 14
Leading therapy areas 14
Leading prescription pharmaceutical brands 14
Leading pharmaceutical companies 14
Australia - Drug expiry analysis 16
Generics market 16
Brand erosion post patent expiry 16
Biosimilars market 16
Australia - Pharmaceutical industry infrastructure analysis 18
Pharmaceutical industry infrastructure overview 18
R&D infrastructure trends 18
Manufacturing infrastructure trends 19
Related reports 20
Upcoming related reports 20
Table of Contents 20
2. Australia - Socio-demographic and economic Analysis 21
Key findings 21
Socio-demographic trends 21
Socio-economic trends 21
Demographic trends in Australia 22
High population growth is a hot topic in Australia 22
Australia's birth rate is expected to stabilize 24
Proportion of elderly individuals is set to rise 25
Australia's life expectancy is one of the highest compared with other markets 26
Australia is a culturally and ethnically diverse country 27
Ischemic heart disease tops disease burden in Australia 28
Political climate in Australia 32
Federal elections are set for August 21, 2010 32
The 2010-11 Budget shows that the government's priorities include reforms in health and hospitals 32
Memorandum of Understanding (MoU) is good for innovators, but not so good for generics companies 33
Fifth Community Pharmacy Agreement was received positively all around 34
Australia's economy performs relatively well despite global downturn 35
Australia is doing comparatively well in the face of the global financial crisis 35
Unemployment rate experienced a small setback 37
Business environment in Australia 40
Corporate tax rate is high compared with other medium-sized OECD countries, but likely to be lowered 40
Unexpected price cuts led to uncertainty in Australia's pharmaceutical business environment 40
Historically strong Australian biotechnology industry took a big hit from global downturn 41
3. Australia - Healthcare system and drug regulatory analysis 43
Key findings 43
Healthcare expenditure 43
Healthcare system overview 43
Regulatory issues 43
Pricing and reimbursement issues 44
Healthcare expenditure - Australia's growth in pharmaceutical spending is under debate 45
Australia's healthcare system 48
The structure of the Australian healthcare system is complex 48
Reforms aim to decrease complexity and inequalities by changing the funding and governance of health and hospitals 50

For more information please visit :

http://www.aarkstore.com/reports/Australia-Pharmaceutical-Market-Overview-Reforms-and-continued-price-cuts-will-change-the-healthcare-landscape-52384.html

Was this helpful? 0 0 Comments

You're reading Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthca.